Skip Navigation

Nephrology Dialysis Transplantation 2005 20(Supplement 6):vi31-vi36; doi:10.1093/ndt/gfh1096
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kleophas, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kleophas, W.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Dose tailoring strategies in haemodialysis patients: a discussion of case histories

Werner Kleophas

Gemeinschaftspraxis Karlstrasse, Karlstrasse, Düsseldorf, Germany

Correspondence and offprint requests to: Dr Werner Kleophas, Gemeinschaftspraxis Karlstrasse, Karlstrasse 17–19, D-40210 Düsseldorf, Germany. Email: Kleophas{at}nierenpraxis.de

Tailoring of the epoetin dose to the needs, clinical condition and circumstances of individual patients with renal anaemia offers potential for optimizing the benefits and costs of epoetin therapy. This can be achieved through alterations to dosing frequency, administration route and/or delivery device. Two case histories are presented to illustrate dose tailoring of epoetin therapy in daily clinical practice. The first patient was a man aged 23 years with renal failure secondary to vasculitis. Haemoglobin (Hb) levels were stable during treatment with subcutaneous (s.c.) epoetin-ß. Switching to intravenous (i.v.) epoetin-ß required, after a 5 month period of complex dose adjustments, a 50% increase in the dose of epoetin-ß to maintain Hb levels. The second patient was a woman aged 50 years with diabetic nephropathy. She self-administered epoetin-ß via the Reco-Pen® device to maintain stable Hb levels. Epoetin-ß is approved for administration at dosing frequencies ranging from three times weekly to once every 2 weeks, is safe and effective whether administered by the s.c. or i.v. route and is available in a range of delivery devices. Epoetin-ß therapy can be easily tailored according to the needs, preferences and circumstances of individual patients, thereby maximizing treatment outcomes.

Keywords: administration route; anaemia; device; dose tailoring; epoetin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.